XML 44 R30.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Intangible Assets and Royalty Agreement (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible assets activity summary | Intangible assets are summarized as follows (in thousands):
|  |  |  | December 31,
|  |  |  | 2015 |  | 2014
|  | Weighted Average Amortization Lives |  | Cost |  | Cost
Licenses (a) (b) |  | 10 years |  | $ | 1,009 |  |  | $ | 1,009 |
Patents & Know How (b) |  | 17 years |  | 8,001 |  |  | 7,891 |
Customer & Supplier Relationships (b) |  | 14 years |  | 3,761 |  |  | 3,761 |
Tradenames & Trademarks (b) |  | indefinite |  | 1,008 |  |  | 1,008 |
In Process Research & Development (b) |  | n/a |  | 25 |  |  | 25 |
Patents in Process (c) |  | n/a |  | 1,823 |  |  | 1,082 |
Total |  |  |  | 15,627 |  |  | 14,776 |
Less Accumulated amortization |  |  |  | (4,864 | ) |  | (3,931 | )
Net |  |  |  | $ | 10,763 |  |  | $ | 10,845 |
(a) | On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.
(b) | On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.
(c) | Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
Estimated future amortization expense of intangible assets | Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands):
| Estimated
| Amortization
Year ending December 31, | Expense
2016 | $ | 936 |
2017 | 846 |
2018 | 836 |
2019 | 836 |
2020 | 836 |
Thereafter | 5,465 |
| $ | 9,755 |

X
- Definition Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. + References No definition available. + Details
Name: | mdxg_ScheduleOfIntangibleAssetsActivityTableTextBlock
Namespace Prefix: | mdxg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration